Company news
Candel Therapeutics, Inc. (NASDAQ:CADL) news
Candel Therapeutics, Inc. news releases on 6ix. Latest, Oct 2, 2026: Candel Therapeutics to Present at the SITC 2026 Annual Meeting
Press releases & updates
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
October 2, 2026
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
October 1, 2026
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
October 1, 2026
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate ...
September 30, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2026
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
September 30, 2026
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
September 30, 2026
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
September 29, 2026
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
September 29, 2026
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
September 10, 2026
Candel Therapeutics to Present at September Investor Conferences
August 26, 2026
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 13, 2026
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
August 3, 2026
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
July 29, 2026
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 8, 2026
July 9, 2026
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 8, 2026
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec in Advanced Non-Small Cell Lung Cancer
July 1, 2026
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
June 30, 2026
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
June 25, 2026
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
June 1, 2026
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
May 15, 2026
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 14, 2026
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
May 4, 2026
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
April 29, 2026
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
March 17, 2026
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 11, 2026
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
March 9, 2026
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
February 24, 2026
Candel Therapeutics Announces Proposed $100 Million Public Offering
February 19, 2026
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
February 19, 2026
Candel Therapeutics Announces Pricing of Public Offering
February 18, 2026
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
February 11, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 2, 2026
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
November 17, 2025
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 13, 2025
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
November 4, 2025
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
November 3, 2025
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
October 16, 2025
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
October 14, 2025
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
October 14, 2025
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
October 3, 2025
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
September 29, 2025
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
September 17, 2025
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
September 2, 2025
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
August 28, 2025
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 14, 2025
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
July 30, 2025
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
July 24, 2025
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
July 9, 2025
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
June 24, 2025